Medical University of Vienna-ko ikertzaileekin lankidetzan egindako argitalpenak (9)

2024

  1. Needs assessment for creation of a platform trial network in metabolic-dysfunction associated steatohepatitis

    Communications Medicine, Vol. 4, Núm. 1

2022

  1. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation

    Journal of Hepatology, Vol. 77, Núm. 4, pp. 991-1004

2021

  1. TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms

    Gut, Vol. 70, Núm. 7, pp. 1345-1361

2019

  1. Fine-Tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease

    Hepatology, Vol. 69, Núm. 2, pp. 699-716

  2. Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage

    Gut, Vol. 68, Núm. 3, pp. 533-546

  3. The challenges of primary biliary cholangitis: What is new and what needs to be done

    Journal of Autoimmunity, Vol. 105

2018

  1. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1335-1344

2016

  1. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)

    Nature Reviews Gastroenterology and Hepatology, Vol. 13, Núm. 5, pp. 261-280

2013

  1. The significance of genetics for cholangiocarcinoma development

    Annals of Translational Medicine, Vol. 1, Núm. 3